How to Incorporate MRI and PET Imaging Into Clinical Practice for Prostate Cancer Management-AM2018
Panel moderators will provide a clinical overview with cases to frame the session.
The speakers are experts in prostate imaging and will:
- Provide overview of their technology, including availability, shortcomings and upcoming advances
- Discuss use of each imaging modality in three scenarios:
- Diagnosis/staging/risk stratification;
- Restaging after local therapy and biochemical recurrence; and
- Monitoring for response after systemic therapy.
- Example discussion points - how does mpMRI staging change risk categorization? Is hemeMRI for LN involvement helpful/being utilized? Should MRI fusion biopsies become standard of care and in what population? NaF and/or F-choline PET and SPECT therapy – how to apply technology in initial staging, after biochemical response? How do radiation oncologists assess quality of these advanced imaging modalities?
This activity is available from January 11, 2019, through 11:59 p.m. Eastern time on January 10, 2022.
This activity was originally recorded at ASTRO’s 2018 Annual Meeting, October 22-24, 2018 in San Antonio, TX.
This course is designed to meet the interests of radiation oncologists, surgeons, radiation oncology residents, nurses, radiation therapists, pathologists and diagnostic radiologists.
- Apply advanced imaging technologies (MRI, PET, SPECT) to appropriate medical scenarios.
- Describe upcoming advances in prostate cancer imaging.
Mohummad Siddiqui, MD is employed by the University of Maryland and receives compensation/remuneration/funding from Abilis Life Sciences.
Ashesh Jani, MD holds a leadership position with ADROP and has no financial relationships with a commercial interest.
Robert Karnes, MD receives compensation/remuneration/funding from GenomeDx/Decipher.
Additionally, the SA-CME Task Force and the CME/MOC Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
- No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
- No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
- ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.